dromlakhani Testosterone therapy as symptomatically indicated for low testosterone levels
STEP 1 — Gather Information
Confirm low total testosterone (<300 ng/dL) on two morning samples; assess for hypogonadism symptoms (low libido, erectile dysfunction, fatigue, decreased muscle mass, mood changes); screen for contraindications (prostate/breast cancer, untreated severe sleep apnea, hematocrit >54%).
→ Proceed to step 2 if low testosterone and symptoms are present.
STEP 2 — Rule In / Rule Out
Is the patient symptomatic for hypogonadism?
- Yes: Rule in testosterone therapy for symptom relief; proceed to step 3.
- No: Rule out testosterone therapy for lipid/CV risk reduction; do not initiate therapy.
→ Decision based on symptom presence.
STEP 3 — Classify or Stratify
Are there contraindications to testosterone therapy?
- No contraindications: Proceed to step 4.
- Contraindications present: Do not initiate testosterone therapy; address underlying condition or consider alternatives.
→ Decision based on safety assessment.
STEP 4 — Decide
If symptomatic low testosterone and no contraindications, suggest testosterone therapy (gel, injection, or patch) for symptom improvement; monitor efficacy and adverse effects at 3–6 months.
→ Initiate therapy or withhold based on benefit-risk assessment.
Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone to improve dyslipidemia or reduce cardiovascular disease risk; avoid in prostate/breast cancer, uncontrolled severe sleep apnea, hematocrit >54%; monitor PSA, hematocrit, lipids, liver enzymes; discontinue if adverse effects occur or no symptom improvement.
Concrete Clinical Example
A 58-year-old man with total testosterone 260 ng/dL on two morning samples reports low libido and fatigue; after ruling out prostate cancer and sleep apnea, testosterone gel is initiated for symptom improvement.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Newman CB et al., 2020, doi:10.1210/clinem/dgaa674